SCHEMBL6498971

SCHEMBL6498971

Cc1ccc(-c2cc(C)ccc2C(=O)O)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC7 Q8WUI4 1/20 0.57
MCL1 Q07820 2/20 0.55
CSNK2A1 P68400 1/20 0.52
SMN1; SMN2 Q16637 3/20 0.51
PRKAB2 O43741 1/20 0.49
PRKAG1 P54619 1/20 0.49
PRKAA2 P54646 1/20 0.49
PRKAA1 Q13131 1/20 0.49
PRKAG3 Q9UGI9 1/20 0.49
PRKAG2 Q9UGJ0 1/20 0.49
PRKAB1 Q9Y478 1/20 0.49
AKR1C2 P52895 1/20 0.49
AKR1C1 Q04828 1/20 0.49
POLB P06746 1/20 0.46
KMT2A Q03164 2/20 0.45
NPC1 O15118 1/20 0.45
GAA P10253 1/20 0.45
RAB9A P51151 1/20 0.45
ALDH1A1 P00352 2/20 0.45
HSD17B10 Q99714 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11154359 0.91 ALDH1A1 (0.55) HDAC7MCL1CSNK2A1SMN1; SMN2POLB
SCHEMBL9683573 0.91 HSD17B10 (0.58) HDAC7MCL1CSNK2A1SMN1; SMN2PRKAB2
SCHEMBL3229733 0.90 HDAC7 (0.70) HDAC7CSNK2A1AKR1C2AKR1C1POLB
SCHEMBL6500578 0.89 HDAC7 (0.51) HDAC7MCL1CSNK2A1SMN1; SMN2PRKAB2
SCHEMBL6489883 0.89 NPC1 (0.51) HDAC7MCL1CSNK2A1SMN1; SMN2PRKAB2
SCHEMBL30832923 0.88 MCL1 (0.58) HDAC7MCL1CSNK2A1SMN1; SMN2PRKAB2
SCHEMBL8673355 0.87 CSNK2A1 (0.59) HDAC7MCL1CSNK2A1SMN1; SMN2POLB
SCHEMBL9683494 0.87 HSD17B10 (0.58) HDAC7MCL1CSNK2A1SMN1; SMN2PRKAB2
SCHEMBL9423281 0.87 ALDH1A1 (0.55) HDAC7MCL1CSNK2A1SMN1; SMN2PRKAB2
SCHEMBL11491969 0.86 HDAC7 (0.51) HDAC7MCL1CSNK2A1SMN1; SMN2AKR1C2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-4126755-A Process for the preparation of dimethyl terephthalate DYNAMIT NOBEL AKTIENGESELLSCHAFT (DE) 1978-11-21 US claimed
US-12398120-B2 Substituted hydantoinamides as ADAMTS7 antagonists BAYER AKTIENGESELLSCHAFT (DE) 2025-08-26 US disclosed
EP-4058448-B1 HYDANTOIN DERIVATIVES AS ADAMTS7 ANTAGONISTS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES BAYER AG (DE) 2024-05-29 EP disclosed
US-20230027346-A1 SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS BAYER AKTIENGESELLSCHAFT (DE) 2023-01-26 US disclosed
EP-4058448-A1 SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS Bayer Aktiengesellschaft (DE) 2022-09-21 EP disclosed
WO-2021094436-A1 SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS BAYER AKTIENGESELLSCHAFT (DE) 2021-05-20 WO disclosed
EP-3822268-A1 SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS Bayer Aktiengesellschaft (DE) 2021-05-19 EP disclosed
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors DAISO CO., LTD. (JP) 2005-02-17 US disclosed
US-20040157866-A1 Amide compounds FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-08-12 US disclosed
EP-0879814-B1 Triaromatic compounds, compositions containing them and uses thereof CT INTERNAT DE BR RECH S DERMA (FR) 2001-11-28 EP disclosed
EP-0879814-A1 Triaromatic compounds, compositions containing them and uses thereof CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (C.I.R.D. GALDERMA) (FR) 1998-11-25 EP disclosed
US-4126755-A Process for the preparation of dimethyl terephthalate DYNAMIT NOBEL AKTIENGESELLSCHAFT (DE) 1978-11-21 US disclosed
US-4092481-A METHANOL, DISTILLATION DYNAMIT NOBEL AKTIENGESELLSCHAFT (DT) 1978-05-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12398120-B2 Substituted hydantoinamides as ADAMTS7 antagonists ADAMTS7, MMP7, ADAM17 HDAC7 154/4885MCL1 3739/4885CSNK2A1 3903/4885
US-20040157866-A1 Amide compounds APOB, NR1H2, NR1H3 HDAC7 975/4885MCL1 1945/4885CSNK2A1 484/4885
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors APOB, APOL1, CTRB2 HDAC7 876/4885MCL1 2690/4885CSNK2A1 339/4885
US-20230027346-A1 SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS ADAMTS7, MMP7, ADAM17 HDAC7 154/4885MCL1 3739/4885CSNK2A1 3903/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.